Castro-Varela Alejandra, Molina Sofia, Grosu Horiana B
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
School of Medicine and Health Sciences, Tecnológico de Monterrey, Monterrey, MEX.
Cureus. 2021 Mar 30;13(3):e14189. doi: 10.7759/cureus.14189.
A 63-year-old male with non-small-cell lung cancer (NSCLC) developed a tracheomediastinal fistula after endobronchial ultrasound transbronchial needle aspiration while on treatment with bevacizumab. This vascular endothelial growth factor-specific angiogenesis inhibitor is a first-line treatment for unresectable or metastatic NSCLC and has been reported to cause fatal non-gastrointestinal fistulas. Respiratory tract fistulas are a known rare complication after bevacizumab therapy characterized by a high mortality rate.
一名63岁的非小细胞肺癌（NSCLC）男性患者在接受贝伐单抗治疗期间，经支气管超声引导下经支气管针吸活检术后发生了气管纵隔瘘。这种血管内皮生长因子特异性血管生成抑制剂是不可切除或转移性NSCLC的一线治疗药物，据报道可导致致命的非胃肠道瘘。呼吸道瘘是贝伐单抗治疗后已知的罕见并发症，死亡率很高。
